Shire's Fosrenol Gets FDA Nod, Will Be Available By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Fosrenol will compete directly with Genzyme's Renagel; both products are non-calcium, non-aluminum containing phosphate binders. Shire estimates that less than one-third of the 800,000 ESRD patients with elevated phosphate levels are able to control their phosphorus levels with existing medications.
You may also be interested in...
Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year
Enzyme-replacement sales strong as firm builds on renal franchise.
Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year
Enzyme-replacement sales strong as firm builds on renal franchise.
Fosrenol Approved In Higher Dose Formulation
FDA has approved a higher dose formulation for the end-stage renal disease agent Fosrenol (lanthanum), Shire announced Nov. 28